ERA4TB (European Accelerator of Tuberculosis Regime) project

Team :

  • Team Leader: Nicolas Willand – Professor
  • Dr Maxime Eveque – Engineer
  • Catherine Piveteau – Engineer

Collaborators :

  • Dr Alain Baulard, CIIL, Institut Pasteur Lille
  • Dr Ruben Hartkoorn, CIIL, Institut Pasteur Lille
  • Dr Priscille Brodin, CIIL, Institut Pasteur Lille
  • Dr Philip Supply, CIIL, Institut Pasteur Lille
  • Dr Cyril Gaudin, CIIL, Institut Pasteur Lille

ERA4TB (European Accelerator of Tuberculosis Regime) project is a public-private initiative devoted to accelerate the development of new treatment regimens for tuberculosis.

The ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative dedicated to the development of drugs against tuberculosis. With a team of more than thirty organizations and a budget of over 200 million euros ERA4TB will focus on developing a new, improved tuberculosis treatment. The partners will share their expertise, knowledge and resources to rapidly progress new candidate drugs into clinical trials.

ERA4TB is sponsored by the European Union’s Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative 2 Joint Undertaking and part of the AMR Accelerator umbrella.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, and in-kind support from EFPIA, TB Alliance, Bill & Melinda Gates Foundation and University Of Dundee.

TOP